EU/3/12/1022: Orphan designation for the treatment of familial partial lipodystrophy
Table of contents
On 17 July 2012, orphan designation (EU/3/12/1022) was granted by the European Commission to Aptiv Solutions (UK) Limited, United Kingdom, for metreleptin for the treatment of familial partial lipodystrophy.
The sponsorship was transferred to Bristol-Myers Squibb / AstraZeneca EEIG, United Kingdom, in February 2014 then to AstraZeneca AB, Sweden, in April 2014 and subsequently to Aegerion Pharmaceuticals Limited, United Kingdom, in March 2015.
The sponsorship was transferred to Aegerion Pharmaceuticals B.V., The Netherland, in November 2017.
Metreleptin for treatment of familial partial lipodystrophy has been authorised in the EU as Myalepta since 30 July 2018.
The sponsorship was transferred to Amryt Pharmaceuticals Designated Activity Company, Ireland, in March 2020.
Treatment of familial partial lipodystrophy
|Orphan designation status||
|EU designation number||
|Date of designation||
Amryt Pharmaceuticals Designated Activity Company
Review of designation
The Committee for Orphan Medicinal Products reviewed the orphan designation of Myalepta at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.
More information is available in the orphan medicine assessment report .
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: